Granules India Ltd

Granules India Annual General Meeting

Granules India convened its 35th AGM for August 06, 2026. Agenda includes adopting FY26 financials and approving a Rs.1.75 per share final dividend.

Granules India Annual Report

Granules India Limited submitted its Integrated Annual Report for FY 2025-26. The 35th AGM is scheduled for August 06, 2026, via video conferencing.

Granules India Board Meeting Date

Granules India Ltd will hold a board meeting on 21 July 2026 to approve its unaudited Q1 results. Insider trading window remains closed till 23 July 2026.

Granules India Product Launch

Granules India secured Sole First-to-File ANDA status for Sodium Oxybate Extended-Release. This milestone strengthens its complex generics portfolio in the US market.

Granules India Earnings Call: Key Takeaways

Granules India reported Q3FY26 revenue of ₹13,879 Mn (up 22% YoY) and PAT of ₹1,502 Mn (up 28% YoY), driven by Finished Dosage growth in North America and Europe.

Granules India Business Update

Granules India's US subsidiary received a USFDA EIR with VAI classification for its Chantilly facility. The report concludes a March 2026 inspection involving four observations.

Granules India Earnings Call: Key Takeaways

Granules India reported Q3FY26 revenue of ₹13,879 Mn with a 22% YoY growth. Strategy focuses on shifting from integrated to complex generics, supported by R&D and US portfolio expansion.

Granules India Price Movement Clarification

Granules India clarified that recent trading volume spurts are purely market-driven. The company confirmed compliance with all SEBI price-sensitive disclosure requirements.

Granules India Earnings Call: Key Takeaways

Granules India delivered record performance in FY26, crossing INR 5,000 Cr revenue with 65% gross margins. Management focused on complex generics and the successful integration of Senn Chemicals' peptide business.

Granules India Earnings Call: Key Takeaways

Granules India delivered a strong Q3FY26 with 22% YoY revenue growth, despite a temporary EBITDA loss in its Acyl-S peptide CDMO business. Operating performance improved on execution and leverage.

Granules India Management Change

Granules India Limited has assigned Mr. Harsha Chigurupati, currently an Executive Director, the additional charge of Head of Transformation & Information Technology. The change is effective from April 30, 2026, following board approval. This move reflects a leadership expansion within the company's senior management team.

Granules India Dividend

Granules India Limited has recommended a final dividend of Rs 1.75 per equity share for the financial year 2025-26. The record date is set for July 30, 2026, with the dividend payment expected to be completed by September 4, 2026, subject to shareholder approval at the upcoming General Meeting.

Granules India Dividend

Granules India Limited has fixed July 30, 2026, as the record date to determine shareholders eligible for the final dividend for the financial year ended March 31, 2026. This announcement follows SEBI listing regulations and provides timeline clarity for investors.

Granules India Fund Raise of ₹665.6 Cr

Granules India Limited filed its Monitoring Agency Report for the quarter ended March 31, 2026. The company has received ₹665.63 Crore from a preferential issue of equity shares and warrants. India Ratings & Research confirmed there are no deviations from the stated objects of the issue.

Value

₹665.6 Cr

Granules India Earnings Call: Key Takeaways

Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift toward high-margin Complex Generics and Peptide CDMO.

Granules India Results Update

Granules India reported Q4FY26 revenue of ₹1470.6 Crore, up 23% YoY, with PAT rising 33% to ₹201.6 Crore. Annual FY26 revenue reached ₹5,365.6 Crore, a 20% growth. Performance was driven by portfolio expansion and the Peptides CDMO platform, alongside significant debt reduction and improved ROCE of 17.6%.

Value

₹1,471 Cr

Granules India Earnings Call: Key Takeaways

Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift towards high-margin Complex Gx and Peptide CDMO segments.

Granules India Earnings Call: Key Takeaways

Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift toward high-margin Complex Gx and Peptide CDMO.

Granules India Management Change

Granules India Limited has designated Executive Director Mr. Harsha Chigurupati as Senior Management Personnel (SMP) effective April 30, 2026. He will lead Transformation, Information Technology, Project Management, and Leadership Hiring. The appointment aims to strengthen the company's senior leadership and strategic oversight.

Granules India Financial Results

Granules India Limited reported consolidated total income of ₹5,385.97 Crore for FY 2025-26. The Board recommended a final dividend of ₹1.75 per share. Key developments include the acquisition of Senn Chemicals AG and a USFDA warning letter for the Gagillapur facility, which impacted production and revenue.

Value

₹5,386 Cr

Granules India Q4 FY26 Results: Net Profit ₹201.6 Cr, Up 32.6% YoY

Granules India Ltd reported revenue from operations of ₹1,471 Cr (+22.8% YoY) and net profit of ₹201.6 Cr (+32.6% YoY) for Q4 FY26.

Key figure

Net profit ₹201.6 Cr · +32.6% YoY

Granules India Financial Results

Granules India approved audited financial results for FY 2025-26 and recommended a final dividend of Rs. 1.75 per share (175%). Standalone annual net profit reached ₹400.67 Crore. The company also fixed its 35th AGM for August 06, 2026, and a dividend record date of July 30, 2026.

Granules India Board Meeting Outcome

Granules India Limited has scheduled a Board Meeting on April 29, 2026. The board will consider audited financial results for Q4 and FY2025-26 and recommend a final dividend. The insider trading window remains closed until May 1, 2026.

Granules India Q3 FY26 Results: Net Profit ₹150 Cr, Up 27.1% YoY

Granules India Ltd reported net profit of ₹150 Cr (+27.1% YoY) for Q3 FY26.

Key figure

Net profit ₹150 Cr · +27.1% YoY

Granules India Debt & Borrowing

Granules India Ltd has submitted its initial disclosure confirming it does not fall under the Large Corporate category as per SEBI criteria. The company reported zero outstanding borrowings as of the relevant financial period and committed to informing the exchange if its status changes in the future.

Granules India Business Update

Granules India's US subsidiary, GPI, completed a routine US FDA cGMP audit at its Chantilly, Virginia site with four procedural observations. The inspection, conducted from March 30 to April 3, 2026, reported no data integrity issues. The company committed to addressing the observations within stipulated timelines to maintain regulatory compliance.

Execution

March 30 to April 3, 2026